BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15530262)

  • 1. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck.
    Homma A; Shirato H; Furuta Y; Nishioka T; Oridate N; Tsuchiya K; Nagahashi T; Aoyama H; Inuyama Y; Fukuda S
    Cancer J; 2004; 10(5):326-32. PubMed ID: 15530262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
    Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
    Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
    Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
    Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
    Porceddu SV; Campbell B; Rischin D; Corry J; Weih L; Guerrieri M; Grossi M; Peters LJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):365-73. PubMed ID: 15380568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
    Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.
    Gómez-Millán J; Toledo MD; Lupiañez Y; Rueda A; Trigo JM; Sachetti A; Medina JA
    Clin Transl Oncol; 2013 Apr; 15(4):321-6. PubMed ID: 22911552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
    Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
    Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in non-resectable locally advanced (stage IV-B) squamous cell head and neck carcinoma and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
    Rivera F; Vega-Villegas ME; López-Brea MF; García-Castaño A; de Juan A; Ramos FJ; Collado A; Galdós P; Rubio A; del Valle A; Rama J; Mayorga M; Sanz-Ortiz J
    Clin Transl Oncol; 2007 Jan; 9(1):40-7. PubMed ID: 17272229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
    Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
    Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
    Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
    Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous carboplatin and radiotherapy for all stages of head and neck squamous cell carcinoma.
    Hosokawa Y; Kamada T; Shirato H; Ohmori K; Yasuda M; Yahata H; Nishioka T; Kitahara T; Arimoto T; Inuyama Y
    Clin Oncol (R Coll Radiol); 1995; 7(3):168-72. PubMed ID: 7547519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
    Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
    Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Saxton JP; Lorenz RR; Wood BG; Scharpf J; Ives DI
    Head Neck; 2012 Nov; 34(11):1517-23. PubMed ID: 22180262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.